Overactive BladderNCT00793611
Hypnotherapy for Treatment of Overactive Bladder
A study testing hypnotherapy in people with Overactive Bladder, run by University of New Mexico.
Trial summary
The investigators purpose is to perform a pilot study evaluating the efficacy in hypnotherapy in treating women with Overactive Bladder Symptoms (urinary urgency symptoms and urinary frequency). Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Overactive Bladder
- What is being tested?
- hypnotherapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- Nov 2008to Mar 2010
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- More than 8 voids/day
- Score > 8 on OABq questionnaire
- English speaking
Who cannot join
- Pregnancy
- Less than 18 years old
- History of Schizophrenia or Bipolar Disorder
About this study
Official title: Hypnotherapy for Treatment of Overactive Bladder: A Feasibility Study
The investigators purpose is to perform a pilot study evaluating the efficacy in hypnotherapy in treating women with Overactive Bladder Symptoms (urinary urgency symptoms and urinary frequency). Approximately half the women in the study will receive "standard care" (performing a voiding diary, Pelvic Floor exercises, and timed voiding) and the other half will receive "standard care" and 3 hypnotherapy sessions. The investigators will compare the groups using a validated overactive bladder questionnaire and compare voiding diaries to evaluate urinary frequency at the end of the sessions/study completion.
Read the detailed description
Experimental Design and Methods:
- This is a feasibility study (prior to performing a larger randomized controlled trial at a later date) evaluating whether hypnotherapy effectively treats Overactive Bladder (OAB). Ultimately, for the larger study, in order to find a 20% difference between the hypnotherapy group and controls, we will need to evaluate a total of approximately 66-70 women to find a 20% difference between groups, assuming 80% power and P=0.05. However, the purpose of this pilot study is to evaluate the feasibility of the larger study and determine the appropriate control intervention and outcomes. We plan to evaluate approximately ten subjects (approximately twenty overall) in both the control and hypnotherapy groups. ii) Patients OAB will be offered entry into the study. a) Inclusion criteria: women experiencing 8 voids/day and an OAB Awareness tool score greater than 8. b) Exclusion criteria: males (since we do not care for males in the gynecology clinic), non-English speakers, pregnant women, women younger than 18 years old, incarcerated women, women with a history of bipolar disorder or schizophrenia, women unwilling to undergo hypnotherapy iii) Informed consent will be obtained. iv) Prior to receiving interventions, patients will be administered the OAB-q \& instructed to keep a 3 day voiding diary. If the patient has not had a pelvic exam in the urogynecology clinic within the last year, a pelvic exam will be performed.
- The usual standard treatments for OAB include pelvic floor exercise, voiding diaries, bladder drills (increasing time between voids), and anti-cholinergic medications. The control group will be offered any or all of our standard treatments, including Behavioral treatment (review of voiding diaries and instruction regarding behavioral changes). Both groups will be allowed to continue current OAB medications but asked not to start new medications. The hypnotherapy group will also be offered any or all of our standard treatments, but they will be given the option of receiving hypnotherapy in addition to the usual treatments. vi) Hypnotherapy sessions: Dr. Sapien will conduct 3 hypnotherapy session to women randomized to the hypnotherapy group. These sessions will occur approximately every1-2 weeks over approximately a time span of 6-8 weeks. The sessions will last 60-90 minutes. Session #1) Explain hypnotherapy and practice suggestion therapy; Session #2) address emotions around OAB and life impact, visualization of pelvic floor exercise mechanics, teach self hypnosis; Session #3) address emotions, further practice on exercises and self-hypnosis vii) Blinding of Investigators and Allocation Concealment: Randomization will be performed by the CTSC using computer generated allocation. Only the CTSC personnel will know the assignment schema. Researchers will not know the group assignments. A research nurse otherwise uninvolved in the study will place the group assignments in serially numbered, opaque envelopes. Once subjects sign consents they will receive an opaque envelop assigning them to the Behavioral Therapy or Hypnotherapy group. The individual responsible for data collection and data entry will not know the group assignment until the end of the study when the assignment code is broken.
VI. Human Subjects:
- See inclusion \& exclusion criteria described previously. Children, prisoners and mentally ill or disabled subjects will be excluded from our study. Women who are pre-menopausal and who are not using contraception and have missed a menstrual period will be offered a pregnancy test in the clinic, as is the standard of care in the gynecology clinic. Pregnancy is an exclusion criteria for study participation.Women evaluated in the Gynecology Clinic at the University of New Mexico will be offered participation in the study. ii) Women will be offered study participation in a private setting at their gynecology visit if have the symptoms of OAB noted previously (V.ii).The study will be described verbally and they will receive a copy of the consent form to read. They will be given the option of taking the consent home to have time to consider whether they would like to participate. If the patient wishes more time to consider whether she would like to participate, she will be asked whether she would agree to phone follow-up by a study investigator. If she agrees, she will have phone follow-up at least 24 hours after her clinic visit. If the patient expresses interest in participating in the study, she will then return to sign her consent with a study investigator. All patients will be reassured that declining study participation will have no effect on the care that they receive iii) Potential Risks of Hypnotherapy: Potential Risks of Hypnotherapy: Risks of hypnotherapy are minimal. Hypnosis is a natural state of mind in which the subconscious is accessed and utilized to make a positive impact. Although, in the 1980 false memory syndrome was described with the use of hypnotherapy in child abuse survivors, the current practice of hypnotherapy uses a much different approach to this therapeutic application. Current practice includes open-ended lines of questioning as opposed to suggestive or leading lines of questioning utilized with these victims.
Risks will be minimized by using open-ended lines of questioning for all hypnotherapy sessions (see above). For this study the hypnotherapist is also a physician, therefore physician-patient confidentiality guidelines are in place. Subjects will be asked to contact the PI if they believe that they are suffering from a psychological burden which has occurred from their involvement in the study.
It is highly unlikely that this study would be terminated, as the risks to participants are minimal. However, in the unlikely circumstance that a large number of hypnotherapy subjects complain of severe psychologic or physical discomfort with their hypnotherapy sessions (despite incorporation of relaxation techniques in the sessions), the study would be terminated. Subject case discussion will be conducted by the research team in a private setting
Potential Risks to Control Group: The control group will be offered standard care for treatment of OAB and will not be exposed to any greater risk than usual for OAB treatments iv) Potential Benefits of Hypnotherapy: Alleviating or diminishing symptoms of frequent urinary, urinary urgency and urine leakage.
v)Safety Oversite: The investigators will meet approximately monthly to review study progress and subject issues/complaints. The subjects will have follow-up with either phone or in-person contact with the hypnotherapist or CTSC personnel. If major events, though unlikely, occur, they will be reviewed with appropriate CTSC and HRRC personnel.
vi) After the study is finished, the patients in the control group have the option of undergoing an approx. 20 minute relaxation hypnotherapy session with Dr. Sapien.
- Conditions
- Overactive Bladder
- Being tested
- Behavioral therapy standard of care, hypnotherapy
- Keywords
- Overactive Bladder, Hypnotherapy
- Medical subject headings
- Urinary Bladder, Overactive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Behavioral therapy standard of careBehavioural
Also called behavioral treatment, pelvic floor exercise, bladder drills
controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
hypnotherapyOther
Also called hypnosis
Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
| Study group | Role | What they receive |
|---|---|---|
| Behavioral therapy | Active comparator | "Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)" Receives: Behavioral: Behavioral therapy standard of care |
| hypnotherapy | Experimental | patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder Receives: Behavioral: Behavioral therapy standard of care; Other: hypnotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Overactive Bladder Symptoms (Based on OABqSF)
Scale information; Score ranges for oab-qsf quality of life scores range from 13-78; 13=poor quality of life 78=good quality of life. We reported change scores, with larger negative numbers indicating greater improvement in quality of life scores.
Measured: baseline and approximately 6-12 weeks after study initiation
Secondary outcomes (2)
Change in Voiding Frequency Based on Voiding Diary
change in mean number of voids per 24 hours. Each participant recorded voiding frequency every 24 hours for 3 days at baseline and follow-up. A mean number of voids for every patient over 24 hours was calculated at baseline and follow-up.
Measured: baseline and 6-12 weeks after study initiation
Patient Global Impression of Improvement
Outcome measure is only administered at follow-up and used following treatment in patients with urinary incontinence. Measure varies from 1 to 7 on a Likert scale. 1=very much better and 7=very much worse and 4=no change. Thus, lower numbers represent greater improvement.
Measured: 6-12 weeks after study initiation (@ completion of intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2008 (estimated)
- Study startNov 2008
- Primary completionJan 2010
- Study completionMar 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Overactive BladderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of New Mexico
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yuko Komesu, University of New Mexico
- Investigators
- Yuko M Komesu, MD, Principal investigator, University of New Mexico Health Sciences Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00793611
- Sponsor's protocol ID
- 08-102
- Status last verified
- Sep 2017
- First submitted
- 6 Oct 2008
- Last updated
- 9 Oct 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Freeman RM, Baxby K. Hypnotherapy for incontinence caused by the unstable detrusor. Br Med J (Clin Res Ed). 1982 Jun 19;284(6332):1831-4. doi: 10.1136/bmj.284.6332.1831.
PubMed 6805716
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hypnotherapy for Treatment of Overactive Bladder: A Feasibility Study
- ClinicalTrials.gov ID
- NCT00793611
- Acronym / sponsor ID
- 08-102
- Conditions
- Overactive Bladder
- Keywords
- Overactive Bladder, Hypnotherapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University of New MexicoUniversity, hospital or other
- Study start
- Nov 2008
- Primary completion
- Jan 2010 (actual)
- Study completion
- Mar 2010 (actual)
- First posted
- 19 Nov 2008 (estimated)
- Results
- Posted 28 Oct 2011
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators purpose is to perform a pilot study evaluating the efficacy in hypnotherapy in treating women with Overactive Bladder Symptoms (urinary urgency symptoms and urinary frequency). Approximately half the women in the study will receive "standard care" (performing a voiding diary, Pelvic Floor exercises, and timed voiding) and the other half will receive "standard care" and 3 hypnotherapy sessions. The investigators will compare the groups using a validated overactive bladder questionnaire and compare voiding diaries to evaluate urinary frequency at the end of the sessions/study completion.
Detailed description
Experimental Design and Methods:
- This is a feasibility study (prior to performing a larger randomized controlled trial at a later date) evaluating whether hypnotherapy effectively treats Overactive Bladder (OAB). Ultimately, for the larger study, in order to find a 20% difference between the hypnotherapy group and controls, we will need to evaluate a total of approximately 66-70 women to find a 20% difference between groups, assuming 80% power and P=0.05. However, the purpose of this pilot study is to evaluate the feasibility of the larger study and determine the appropriate control intervention and outcomes. We plan to evaluate approximately ten subjects (approximately twenty overall) in both the control and hypnotherapy groups. ii) Patients OAB will be offered entry into the study. a) Inclusion criteria: women experiencing 8 voids/day and an OAB Awareness tool score greater than 8. b) Exclusion criteria: males (since we do not care for males in the gynecology clinic), non-English speakers, pregnant women, women younger than 18 years old, incarcerated women, women with a history of bipolar disorder or schizophrenia, women unwilling to undergo hypnotherapy iii) Informed consent will be obtained. iv) Prior to receiving interventions, patients will be administered the OAB-q \& instructed to keep a 3 day voiding diary. If the patient has not had a pelvic exam in the urogynecology clinic within the last year, a pelvic exam will be performed.
- The usual standard treatments for OAB include pelvic floor exercise, voiding diaries, bladder drills (increasing time between voids), and anti-cholinergic medications. The control group will be offered any or all of our standard treatments, including Behavioral treatment (review of voiding diaries and instruction regarding behavioral changes). Both groups will be allowed to continue current OAB medications but asked not to start new medications. The hypnotherapy group will also be offered any or all of our standard treatments, but they will be given the option of receiving hypnotherapy in addition to the usual treatments. vi) Hypnotherapy sessions: Dr. Sapien will conduct 3 hypnotherapy session to women randomized to the hypnotherapy group. These sessions will occur approximately every1-2 weeks over approximately a time span of 6-8 weeks. The sessions will last 60-90 minutes. Session #1) Explain hypnotherapy and practice suggestion therapy; Session #2) address emotions around OAB and life impact, visualization of pelvic floor exercise mechanics, teach self hypnosis; Session #3) address emotions, further practice on exercises and self-hypnosis vii) Blinding of Investigators and Allocation Concealment: Randomization will be performed by the CTSC using computer generated allocation. Only the CTSC personnel will know the assignment schema. Researchers will not know the group assignments. A research nurse otherwise uninvolved in the study will place the group assignments in serially numbered, opaque envelopes. Once subjects sign consents they will receive an opaque envelop assigning them to the Behavioral Therapy or Hypnotherapy group. The individual responsible for data collection and data entry will not know the group assignment until the end of the study when the assignment code is broken.
VI. Human Subjects:
- See inclusion \& exclusion criteria described previously. Children, prisoners and mentally ill or disabled subjects will be excluded from our study. Women who are pre-menopausal and who are not using contraception and have missed a menstrual period will be offered a pregnancy test in the clinic, as is the standard of care in the gynecology clinic. Pregnancy is an exclusion criteria for study participation.Women evaluated in the Gynecology Clinic at the University of New Mexico will be offered participation in the study. ii) Women will be offered study participation in a private setting at their gynecology visit if have the symptoms of OAB noted previously (V.ii).The study will be described verbally and they will receive a copy of the consent form to read. They will be given the option of taking the consent home to have time to consider whether they would like to participate. If the patient wishes more time to consider whether she would like to participate, she will be asked whether she would agree to phone follow-up by a study investigator. If she agrees, she will have phone follow-up at least 24 hours after her clinic visit. If the patient expresses interest in participating in the study, she will then return to sign her consent with a study investigator. All patients will be reassured that declining study participation will have no effect on the care that they receive iii) Potential Risks of Hypnotherapy: Potential Risks of Hypnotherapy: Risks of hypnotherapy are minimal. Hypnosis is a natural state of mind in which the subconscious is accessed and utilized to make a positive impact. Although, in the 1980 false memory syndrome was described with the use of hypnotherapy in child abuse survivors, the current practice of hypnotherapy uses a much different approach to this therapeutic application. Current practice includes open-ended lines of questioning as opposed to suggestive or leading lines of questioning utilized with these victims.
Risks will be minimized by using open-ended lines of questioning for all hypnotherapy sessions (see above). For this study the hypnotherapist is also a physician, therefore physician-patient confidentiality guidelines are in place. Subjects will be asked to contact the PI if they believe that they are suffering from a psychological burden which has occurred from their involvement in the study.
It is highly unlikely that this study would be terminated, as the risks to participants are minimal. However, in the unlikely circumstance that a large number of hypnotherapy subjects complain of severe psychologic or physical discomfort with their hypnotherapy sessions (despite incorporation of relaxation techniques in the sessions), the study would be terminated. Subject case discussion will be conducted by the research team in a private setting
Potential Risks to Control Group: The control group will be offered standard care for treatment of OAB and will not be exposed to any greater risk than usual for OAB treatments iv) Potential Benefits of Hypnotherapy: Alleviating or diminishing symptoms of frequent urinary, urinary urgency and urine leakage.
v)Safety Oversite: The investigators will meet approximately monthly to review study progress and subject issues/complaints. The subjects will have follow-up with either phone or in-person contact with the hypnotherapist or CTSC personnel. If major events, though unlikely, occur, they will be reviewed with appropriate CTSC and HRRC personnel.
vi) After the study is finished, the patients in the control group have the option of undergoing an approx. 20 minute relaxation hypnotherapy session with Dr. Sapien.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Behavioral therapy | Active comparator | Behavioral: Behavioral therapy standard of care"Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)" |
| hypnotherapy | Experimental | Behavioral: Behavioral therapy standard of care, Other: hypnotherapypatients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- More than 8 voids/day
- Score > 8 on OABq questionnaire
- English speaking
Key exclusion criteria (3 listed)
- Pregnancy
- Less than 18 years old
- History of Schizophrenia or Bipolar Disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Behavioral therapy standard of careAlso: behavioral treatment, pelvic floor exercise, bladder drillscontrols will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises | Behavioural | Behavioral therapy, hypnotherapy |
| hypnotherapyAlso: hypnosisPatients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder | Other | hypnotherapy |
Primary outcome
Change in Overactive Bladder Symptoms (Based on OABqSF)
Time frame: baseline and approximately 6-12 weeks after study initiation
Scale information; Score ranges for oab-qsf quality of life scores range from 13-78; 13=poor quality of life 78=good quality of life. We reported change scores, with larger negative numbers indicating greater improvement in quality of life scores.
2 secondary outcomes
Change in Voiding Frequency Based on Voiding Diary
Time frame: baseline and 6-12 weeks after study initiation
Patient Global Impression of Improvement
Time frame: 6-12 weeks after study initiation (@ completion of intervention)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 6805716Freeman RM, Baxby K. Hypnotherapy for incontinence caused by the unstable detrusor. Br Med J (Clin Res Ed). 1982 Jun 19;284(6332):1831-4. doi: 10.1136/bmj.284.6332.1831.
Related trials for Overactive Bladder
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
Active, not recruitingObservational study
Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
RecruitingObservational study
Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder
Overactive Bladder (OAB)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yuko M Komesu, MD principal investigator
University of New Mexico Health Sciences Center
Questions about this trial
What is this clinical trial studying?
A study testing hypnotherapy in people with Overactive Bladder, run by University of New Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 28 Oct 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Overactive Bladder Symptoms (Based on OABqSF) (time frame: baseline and approximately 6-12 weeks after study initiation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00793611, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2017.